<DOC>
	<DOCNO>NCT00020748</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness epirubicin plus irinotecan treating patient advance cancer .</brief_summary>
	<brief_title>Epirubicin Plus Irinotecan Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose epirubicin irinotecan patient advance cancer . - Determine objective antitumor response patient treat regimen . - Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study . Patients receive irinotecan IV 1 hour follow epirubicin IV 5 minute day 1 8 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Sequential dose escalation epirubicin follow sequential dose escalation irinotecan . Cohorts 3-6 patient receive escalate dos epirubicin irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-30 patient accrue study .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document incurable malignancy beneficial standard therapy Locally unresectable metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : Ejection fraction least 50 % MUGA scan No congestive heart failure Other : Maintaining reasonable state nutrition No frequent vomit severe anorexia No weight loss great 10 % current body weight within past 4 week No concurrent medical illness would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : Prior doxorubicin allow cumulative dose great 240 mg/m2 Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>